PNC Financial Services Group’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.32K | Buy |
179
+63
| +54% | +$1.88K | ﹤0.01% | 4239 |
|
|
2025
Q4 | $4.43K | Buy |
116
+23
| +25% | +$748 | ﹤0.01% | 4277 |
|
|
2025
Q3 | $2.22K | Buy |
93
+88
| +1,760% | +$1.65K | ﹤0.01% | 4472 |
|
|
2025
Q2 | $74 | Buy |
+5
| New | +$83 | ﹤0.01% | 4854 |
|
|
2025
Q1 | – | Sell |
-20
| Closed | -$348 | – | 5006 |
|
|
2024
Q4 | $348 | Hold |
20
| – | – | ﹤0.01% | 4576 |
|
|
2024
Q3 | $280 | Hold |
20
| – | – | ﹤0.01% | 4638 |
|
|
2024
Q2 | $164 | Sell |
20
-1,019
| -98% | -$6.86K | ﹤0.01% | 4687 |
|
|
2024
Q1 | $8.01K | Buy |
1,039
+771
| +288% | +$6.5K | ﹤0.01% | 3824 |
|
|
2023
Q4 | $2.41K | Sell |
268
-13
| -5% | -$95 | ﹤0.01% | 4153 |
|
|
2023
Q3 | $2.51K | Sell |
281
-664
| -70% | -$9.37K | ﹤0.01% | 4180 |
|
|
2023
Q2 | $14.5K | Buy |
945
+325
| +52% | +$5.91K | ﹤0.01% | 3701 |
|
|
2023
Q1 | $13.9K | Sell |
620
-146
| -19% | -$3.1K | ﹤0.01% | 3654 |
|
|
2022
Q4 | $16.1K | Sell |
766
-10
| -1% | -$212 | ﹤0.01% | 3573 |
|
|
2022
Q3 | $19K | Buy |
776
+24
| +3% | +$620 | ﹤0.01% | 3480 |
|
|
2022
Q2 | $18K | Buy |
752
+42
| +6% | +$1.06K | ﹤0.01% | 3549 |
|
|
2022
Q1 | $18K | Sell |
710
-1
| -0.1% | -$27 | ﹤0.01% | 3634 |
|
|
2021
Q4 | $22K | Sell |
711
-12
| -2% | -$338 | ﹤0.01% | 3510 |
|
|
2021
Q3 | $17K | Buy |
723
+560
| +344% | +$10.3K | ﹤0.01% | 3581 |
|
|
2021
Q2 | $2K | Hold |
163
| – | – | ﹤0.01% | 4059 |
|
|
2021
Q1 | $4K | Hold |
163
| – | – | ﹤0.01% | 3872 |
|
|
2020
Q4 | $4K | Hold |
163
| – | – | ﹤0.01% | 3766 |
|
|
2020
Q3 | $3K | Hold |
163
| – | – | ﹤0.01% | 3773 |
|
|
2020
Q2 | $3K | Hold |
163
| – | – | ﹤0.01% | 3732 |
|
|
2020
Q1 | $2K | Sell |
163
-80
| -33% | -$1.2K | ﹤0.01% | 3755 |
|
|
2019
Q4 | $4K | Buy |
243
+163
| +204% | +$2.08K | ﹤0.01% | 3703 |
|
|
2019
Q3 | $0 | Hold |
80
| – | – | ﹤0.01% | 4111 |
|
|
2019
Q2 | $2K | Sell |
80
-234,812
| -100% | -$4.64M | ﹤0.01% | 3886 |
|
|
2019
Q1 | $5.32M | Sell |
234,892
-71,587
| -23% | -$1.58M | 0.01% | 693 |
|
|
2018
Q4 | $6.93M | Sell |
306,479
-21,378
| -7% | -$532K | 0.01% | 576 |
|
|
2018
Q3 | $9.42M | Buy |
327,857
+55,529
| +20% | +$1.59M | 0.01% | 553 |
|
|
2018
Q2 | $7.42M | Buy |
272,328
+254,232
| +1,405% | +$6.77M | 0.01% | 628 |
|
|
2018
Q1 | $405K | Sell |
18,096
-2,010
| -10% | -$47.9K | ﹤0.01% | 1753 |
|
|
2017
Q4 | $423K | Buy |
+20,106
| New | +$460K | ﹤0.01% | 1739 |
|
|
2016
Q3 | – | Sell |
-163
| Closed | -$3K | – | 4277 |
|
|
2016
Q2 | $3K | Sell |
163
-7
| -4% | -$113 | ﹤0.01% | 4063 |
|
|
2016
Q1 | $2K | Sell |
170
-244
| -59% | -$3.7K | ﹤0.01% | 4219 |
|
|
2015
Q4 | $8K | Sell |
414
-21
| -5% | -$420 | ﹤0.01% | 3690 |
|
|
2015
Q3 | $8K | Buy |
435
+62
| +17% | +$1.84K | ﹤0.01% | 3784 |
|
|
2015
Q2 | $12K | Buy |
373
+87
| +30% | +$2.38K | ﹤0.01% | 3737 |
|
|
2015
Q1 | $7K | Buy |
+286
| New | +$4.36K | ﹤0.01% | 3930 |
|
Other funds holding TVTX
AC
PA
VCM
NAMI
PNC Financial Services Group's TVTX Position: Q1 2026 in Review
PNC Financial Services Group increased its Travere Therapeutics (TVTX) stake by 54% in Q1 2026, buying an estimated $1.88K and bringing the position to 179 shares worth $5.32K. The position accounts for ﹤0.01% of the portfolio, ranked #4239.
PNC Financial Services Group first reported a position in TVTX in Q1 2015 and has held it in 39 quarters since. The position peaked at $9.42M in Q3 2018. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.
- PNC Financial Services Group held 179 shares of Travere Therapeutics worth $5.32K as of Q1 2026.
- PNC Financial Services Group bought 63 Travere Therapeutics shares in Q1 2026, an estimated $1.88K.
- Travere Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q1 2026, its #4239 holding.
- PNC Financial Services Group first reported a position in Travere Therapeutics in Q1 2015 and has held it in 39 quarters since.
- PNC Financial Services Group's Travere Therapeutics position peaked at $9.42M in Q3 2018.
- 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.
Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.